1,743 Shares in Merck & Co., Inc. (NYSE:MRK) Purchased by Strategic Advocates LLC

Strategic Advocates LLC purchased a new position in shares of Merck & Co., Inc. (NYSE:MRKFree Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 1,743 shares of the company’s stock, valued at approximately $230,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Vermillion & White Wealth Management Group LLC acquired a new stake in Merck & Co., Inc. in the fourth quarter valued at about $27,000. Bare Financial Services Inc acquired a new stake in Merck & Co., Inc. in the fourth quarter valued at about $28,000. Burkett Financial Services LLC acquired a new stake in Merck & Co., Inc. in the fourth quarter valued at about $28,000. Rakuten Securities Inc. acquired a new stake in Merck & Co., Inc. in the fourth quarter valued at about $30,000. Finally, RIA Advisory Group LLC acquired a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at approximately $30,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Performance

NYSE:MRK opened at $127.99 on Wednesday. The company has a current ratio of 1.25, a quick ratio of 0.99 and a debt-to-equity ratio of 0.77. The firm has a market capitalization of $324.17 billion, a price-to-earnings ratio of 142.21, a PEG ratio of 2.46 and a beta of 0.39. The firm’s fifty day simple moving average is $128.66 and its 200 day simple moving average is $122.99. Merck & Co., Inc. has a twelve month low of $99.14 and a twelve month high of $133.10.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last posted its earnings results on Thursday, April 25th. The company reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.94 by $0.13. The business had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.21 billion. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.05%. The business’s quarterly revenue was up 8.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.40 EPS. As a group, equities research analysts expect that Merck & Co., Inc. will post 8.64 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, July 8th. Shareholders of record on Monday, June 17th will be issued a $0.77 dividend. The ex-dividend date of this dividend is Monday, June 17th. This represents a $3.08 dividend on an annualized basis and a yield of 2.41%. Merck & Co., Inc.’s dividend payout ratio is currently 342.22%.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on MRK shares. Truist Financial lifted their price target on shares of Merck & Co., Inc. from $142.00 to $143.00 and gave the company a “buy” rating in a research report on Friday, April 26th. Cantor Fitzgerald reiterated an “overweight” rating and set a $155.00 price target on shares of Merck & Co., Inc. in a research report on Tuesday. Argus upgraded Merck & Co., Inc. to a “strong-buy” rating in a research report on Wednesday, June 5th. TheStreet downgraded Merck & Co., Inc. from a “b+” rating to a “c+” rating in a research report on Monday, March 4th. Finally, Wells Fargo & Company lifted their target price on shares of Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 27th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $133.00.

Check Out Our Latest Research Report on MRK

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Further Reading

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.